Slide 1: Q4 & FY'2022 Results
We engineer enzymes Q4 & FY’2022 Results February 23, 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer to sell, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for
Slide 3: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors New management team is well-positioned to lead the Company as it pivots focus to high-value Life Sciences & Biotherapeutics verticals Management Team Stephen Dilly, MBBS, Ph.D. Sri Ryali, MBA Kevin Norrett, MBA Meg Fitzgerald, JD President and Chief
Slide 4: Codexis Snapshot: Core Business Pillars
Codexis Snapshot: Core Business Pillars 3 focus areas based on CodeEvolver®, our proprietary platform leveraging machine learning to accelerate enzyme discovery & commercialization Pharma Manufacturing Life Sciences Biotherapeutics Enzymes for Small Molecule Enzymes for Enzymes for Enzymes as Oral D
Slide 5: Our Most Advanced Biotherapeutics Assets
Our Most Advanced Biotherapeutics Assets CDX-7108 for EPI CDX-6114 for PKU Gene Therapies • Most advanced clinical asset; being • Phenylketonuria (PKU) is one of the • CodeEvolver®-engineered proteins co-developed 50/50 with Nestlé most common inborn errors of optimized for improved targeting and He
Slide 6: CDX-7108 Case Study: Oral Enzyme Therapy for Treatment of EPI
CDX-7108 Case Study: Oral Enzyme Therapy for Treatment of EPI Superior in vitro GI performance CDX-7108 is co-owned (50 / 50 split) with 1 0 CDX-7108 R e a c tio n P ro g re s s 8 • Exocrine Pancreatic Insufficiency (EPI) - impaired pancreatic 6 Enteric coated PERT function due to pancreatitis, panc
Slide 7: CDX-7108: Phase 1 Part A & B Complete; Part C POC Ongoing
CDX-7108: Phase 1 Part A & B Complete; Part C POC Ongoing • Preliminary data from 48 healthy volunteers and 5 subjects with EPI dosed with CDX-7108 • Study examined lipid absorption as measured b 13CO2 excretion • No safety issues were noted • No Serious Adverse Events observed and no treatment disc
Slide 8: Gene Therapy Transgene Case Study: Treatment of Fabry Disease
Gene Therapy Transgene Case Study: Treatment of Fabry Disease Codexis GLA Variant • Codexis has delivered transgenes that encode for enzymes to Takeda for Fabry disease, Pompe disease, and an undisclosed blood factor disorder; a fourth program is in progress • As illustrated by the data shown here f
Slide 9: Commercial Stage Pharmaceutical Manufacturing with a Robust Pipeline
Commercial Stage Pharmaceutical Manufacturing with a Robust Pipeline Market Segment # of Research Development Commercial Example Partner(s) programs Platform Licenses 3 Commercial APIs 18 Phase II/III APIs 18 Multiple Partners Research & Early >50 Multiple Partners Clinical Estimated $3M to $7M mark
Slide 10: Commercial Stage Life Sciences Product Portfolio with a Robust Product Pipeline
Commercial Stage Life Sciences Product Portfolio with a Robust Product Pipeline Product Research Development Commercial Go-to-Market Approach EvoT4™DNA Ligase Partnered with Codex® HiFi Hot Start DNA & Detection Sequencing Wholly-owned Polymerase Codex® HiTemp Reverse Wholly-owned Transcriptase Newl
Slide 11: Engineered RNA Polymerase for Improved mRNA Synthesis
Engineered RNA Polymerase for Improved mRNA Synthesis Codex® HiCap RNA Polymerase Engineered for improved mRNA capping efficiency ~99% capped ~90% capped Key features & benefits 100% • Higher capping efficiency with lower 5’ cap concentration 80% o Increased yields of fully capped mRNA product (2x o
Slide 12: Case Study: TdT Polymerase for Enzymatic DNA Synthesis
Case Study: TdT Polymerase for Enzymatic DNA Synthesis Terminal deoxynucleotidyl transferase (TdT) Game changing approach to disrupt high-growth DNA synthesis market Engineered for improved stability and speed of conversion Codexis engineered TdT Polymerase outperforms current non- enzymatic DNA syn
Slide 13: The Codexis RNAi Synthesis Platform
The Codexis RNAi Synthesis Platform… Our Goal Why We Win ❑ Leverage CodeEvolver® to create an enzymatic ✓ An enzymatic solution can meet the scale required for large indications while phosphoramidite chemistry may not solution for large-scale synthesis of RNAi ✓ Economic & societal incentives for ch
Slide 14: Enhanced Commercial Focus
Enhanced Commercial Focus Pharmaceutical Life Sciences Biotherapeutics Manufacturing ▪ Maintain strong relationships ▪ Continue to design and ▪ Prioritize pipeline assets with top global manufacture enzymes “plug ▪ How much to invest pharmaceutical manufacturers and play” solutions for ▪ When to par
Slide 15: FY 2022 Results
FY 2022 Results Revenue Revenue Excluding Sales Related to PAXLOVIDTM $63.2M $41.3M $138.6M $116.7M FY’22 Revenue Excl. Sales Product Revenue Excl. FY’22 Total Revenue FY’22 Product Related to PAXLOVIDTM Sales Related to (+32% YOY) Revenue (+65% YOY) (-10% YOY) PAXLOVIDTM (+14% YOY) 67% $114.0M Gros
Slide 16: FY 2022 Segment Financials
FY 2022 Segment Financials Performance Enzymes Biotherapeutics $126.6M $12.0M FY’22 Revenue FY’22 Revenue $46.4M ($41.2M) FY’22 Income from FY’22 Loss from Operations1 Operations1 Supported by $38.5M of corporate overhead expense (not allocated to either business segment) 1 Represents total revenues
Slide 17: 2023 Guidance
2023 Guidance $63M–$68M $35M–$40M 68%–73% Total Revenue Product Revenue Product Gross Margin Excluding Sales Related to PAXLOVIDTM Excluding Sales Related to PAXLOVIDTM Cash Runway Through End of 2024 17
Slide 18: Nasdaq: CDXS www.codexis.com
Nasdaq: CDXS www.codexis.com